Enzymatic glycan remodeling-metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering

• Main Authors: Marloes A. Wijdeven (Author), Remon van Geel (Author), Jorin H. Hoogenboom (Author), Jorge M. M. Verkade (Author), Brian M. G. Janssen (Author), Inge Hurkmans (Author), Laureen de Bever (Author), Sander S. van Berkel (Author), Floris L. van Delft (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how the clinical-stage GlycoConnect™ technology uses the globally conserved N-glycosylati...